Literature DB >> 26438499

Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.

S D Kotsakis1, V Miriagou1, E E Vetouli2, E Bozavoutoglou2, E Lebessi2, E Tzelepi3, L S Tzouvelekis4.   

Abstract

The cephalosporinase CMY-107, a Tyr199Cys mutant form of CMY-2 encoded by an IncI self-transferable plasmid carried by an Escherichia coli clinical strain, was characterized. The enzyme hydrolyzed oximino-cephalosporins and aztreonam more efficiently than CMY-2 did.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26438499      PMCID： PMC4649145          DOI： 10.1128/AAC.01793-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Prevalence of a transferable SHV-5 type beta-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece.

Authors:  A C Vatopoulos; A Philippon; L S Tzouvelekis; Z Komninou; N J Legakis
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

4.  Kinetic properties of four plasmid-mediated AmpC beta-lactamases.

Authors:  Cédric Bauvois; Akiko Shimizu Ibuka; Almeida Celso; Jimena Alba; Yoshikazu Ishii; Jean-Marie Frère; Moreno Galleni
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors:  João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

7.  Origin and evolution of the AmpC beta-lactamases of Citrobacter freundii.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.

Authors:  Pia S Pannaraj; Jennifer Dien Bard; Chiara Cerini; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

9.  Biochemical and molecular characterization of three new variants of AmpC beta-lactamases from Morganella morganii.

Authors:  Pablo Power; Moreno Galleni; Juan A Ayala; Gabriel Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Phenotypic and molecular characterization of plasmid mediated AmpC β-lactamases among Escherichia coli, Klebsiella spp., and Proteus mirabilis isolated from urinary tract infections in Egyptian hospitals.

Authors:  Mai M Helmy; Reham Wasfi
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411
View more
  2 in total

1.  Characterization of the First OXA-10 Natural Variant with Increased Carbapenemase Activity.

Authors:  Stathis D Kotsakis; Carl-Fredrik Flach; Mohammad Razavi; D G Joakim Larsson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 2.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.